KinaseNET

Nomenclature

Short Name:

LYN

Full Name:

Tyrosine-protein kinase Lyn

Alias:

EC 2.7.10.2
FLJ13161
LYN
V-yes-1 Yamaguchi sarcoma viral related oncogene
FLJ26625
JTK8
Kinase Lyn
KPM

Classification

Type:

Protein-tyrosine kinase

Group:

Family:

Src

SubFamily:

Specific Links

BioCarta Entry:	bcr pathway
Entrez-Gene Entry:	4067
Entrez-Protein Entry:	NP_002341
GeneCards Entry:	JTK8
KinBASE Entry:	LYN
OMIM Entry:	165120
Pfam Entry:	P07948
PhosphoNET Entry:	P07948
Phosphosite Plus Entry:	618
Protein Data Bank Entry:	1W1F
ScanSite Entry:	P07948
Source Entry:	LYN
UCSD-Nature Entry:	A001441
UniProt Entry:	P07948
Kinexus Products:	LYN Yes-related protein-tyrosine kinase; Tyrosine-protein kinase Lyn pan-specific antibody AB-NK095-2 Yes-related protein-tyrosine kinase; Tyrosine-protein kinase Lyn Y508 phosphosite-specific antibody AB-PK688 CDK1 (6-20) KinSub - Cyclin-dependent kinase 1 (CDC2) (K6-K20, human) peptide; Src protein kinase substrate peptide - Powder PE-01ADT95 Yes-related protein-tyrosine kinase / Tyrosine-protein kinase Lyn (G16-R34, human) peptide - Powder PE-01BDP80 LynSubtide - Lyn protein kinase substrate peptide - Powder PE-01BHY99 Yes-related protein-tyrosine kinase / Tyrosine-protein kinase Lyn (E505-Q511, human) pY508 phosphopeptide - Powder PE-04ANN90

General Links

Structure

Mol. Mass (Da):

58574

# Amino Acids:

512

# mRNA Isoforms:

mRNA Isoforms:

58,574 Da (512 AA; P07948); 56,033 Da (491 AA; P07948-2)

4D Structure:

Interacts with phosphorylated LIME1 and with CD79A upon BCR activation. Interacts with Epstein-Barr virus LMP2A. Interacts with TGFB1I1. Interaction, via the SH2 and SH3, domains with MUC1 is stimulated by IL7 and, the subsequent phosphorylation increases the binding between MUC1 and CTNNB1/beta-catenin. Interacts with PPP1R15A and PDE4A via the SH3 domain. Interacts with Herpesvirus saimiri tyrosine kinase interacting protein (Tip). Interacts with ADAM15. Interacts with NDFIP2 and more weakly with NDFIP1.

1D Structure:

Retrieve Gene Sequence
Retrieve Full Protein Sequence
Retrieve Catalytic Domain Sequence

3D Image (rendered using PV Viewer):

PDB ID

3A4O

Subfamily Alignment

Domain Distribution:

Start	End	Domain
63	123	SH3
129	226	SH2
246	496	TyrKc
247	499	Pkinase

Kinexus Products

Click on entries below for direct links to relevant products from Kinexus for this protein kinase.

hiddentext

○	Yes-related protein-tyrosine kinase; Tyrosine-protein kinase Lyn pan-specific antibody AB-NK095-2
○	Yes-related protein-tyrosine kinase; Tyrosine-protein kinase Lyn Y508 phosphosite-specific antibody AB-PK688
○	CDK1 (6-20) KinSub - Cyclin-dependent kinase 1 (CDC2) (K6-K20, human) peptide; Src protein kinase substrate peptide - Powder PE-01ADT95
○	Yes-related protein-tyrosine kinase / Tyrosine-protein kinase Lyn (G16-R34, human) peptide - Powder PE-01BDP80
○	LynSubtide - Lyn protein kinase substrate peptide - Powder PE-01BHY99
○	Yes-related protein-tyrosine kinase / Tyrosine-protein kinase Lyn (E505-Q511, human) pY508 phosphopeptide - Powder PE-04ANN90

Post-translation Modifications

For detailed information on phosphorylation of this kinase go to PhosphoNET

Myristoylated:

G2.

Palmitoylated:

C3.

Serine phosphorylated:

S11, S13, S115, S149, S158, S164, S228, S246, S269, S283, S326.

Threonine phosphorylated:

T58, T135, T276, T281, T296, T319, T398+, T438, T448, T502-, T503-, T504.

Tyrosine phosphorylated:

Y32, Y117, Y193, Y194, Y265, Y266-, Y306, Y316, Y321, Y397+, Y439, Y460, Y473, Y501, Y508-.

Ubiquitinated:

K9, K20, K59, K477.

Distribution

Based on gene microarray analysis from the NCBI

Human Tissue Distribution

% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:

46

1143

42

1267
4

95

23

45
3

86

14

56
18

442

147

928
34

847

36

660
5

126

111

89
17

411

51

558
44

1079

69

2719
40

988

24

632
3

78

141

50
4

93

50

70
31

768

282

695
10

246

47

111
2

46

21

29
4

90

41

88
4

99

24

41
4

94

366

747
4

101

28

57
2

44

134

26
22

538

162

552
4

87

39

45
21

513

45

335
6

153

25

98
2

39

29

35
3

79

39

55
23

574

89

657
15

372

50

164
8

192

29

83
3

64

29

35
4

106

42

82
24

590

30

599
39

972

51

754
100

2474

88

2512
67

1648

83

600
20

498

48

993

Evolution

Species Conservation

PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:

100

100

100
57.3

68.5

100
80

81.5

99
-

-

97
-

-

98
97

99.2

97
-

-

-
96

98.8

96
96

98.8

96
-

-

-
93.1

96.6

-
63

77.7

88
56.7

72

86
76.3

86.9

77.5
-

-

-
51.4

69.2

-
-

-

-
-

-

-
-

-

-
-

-

-
-

-

-
-

-

-
-

-

-
-

-

-
-

-

-

For a wider analysis go to PhosphoNET Evolution in PhosphoNET

Regulation

Activation:

Inhibition:

Phosphorylation of Thr-503 inhibits phosphotransferase activity.

Synthesis:

Degradation:

Kinections Map

Click here to download a PPT of the image below

Known Upstream Kinases

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.

Based on in vitro and/or in vivo phosphorylation data

Kinase Short Name	UniProt ID (Human)	Phosphosite Location	Phosphosite Sequence	Effect of Phosphorylation

LYN	P07948	Y397	RVIEDNEYTAREGAK	+
CSK	P41240	T503	LDDFYTATEGQYQQQ	-
CTK	P42679	Y508	YTATEGQYQQQP___	-
CSK	P41240	Y508	YTATEGQYQQQP___	-

Known Downstream Substrates

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.

Based on in vitro and/or in vivo phosphorylation data

Substrate Short Name	UniProt ID (Human)	Phosphosite Location	Phosphosite Sequence	Effect of Phosphorylation

Abl1	P00519	Y115	QGWVPSNYITPVNSL
Abl1	P00519	Y128	SLEKHSWYHGPVSRN
Abl1	P00519	Y139	VSRNAAEYLLSSGIN	+
Abl1	P00519	Y172	LRYEGRVYHYRINTA
Abl1	P00519	Y185	TASDGKLYVSSESRF
Abl1	P00519	Y215	GLITTLHYPAPKRNK
Abl1	P00519	Y226	KRNKPTVYGVSPNYD	+
Abl1	P00519	Y393	RLMTGDTYTAHAGAK	+
Abl1	P00519	Y70	PNLFVALYDFVASGD	+
Abl1 iso2	P00519-2	Y134	QGWVPSNYITPVNSL
Abl1 iso2	P00519-2	Y147	SLEKHSWYHGPVSRN
Abl1 iso2	P00519-2	Y158	VSRNAAEYLLSSGIN	+
Abl1 iso2	P00519-2	Y191	LRYEGRVYHYRINTA
Abl1 iso2	P00519-2	Y204	TASDGKLYVSSESRF
Abl1 iso2	P00519-2	Y234	GLITTLHYPAPKRNK
Abl1 iso2	P00519-2	Y245	KRNKPTVYGVSPNYD	+
Abl1 iso2	P00519-2	Y412	RLMTGDTYTAHAGAK	+
Abl1 iso2	P00519-2	Y89	PNLFVALYDFVASGD	+
Bcr	P11274	Y177	ADAEKPFYVNVEFHH	+
Btk	Q06187	Y223	LKKVVALYDYMPMNA	+
Btk	Q06187	Y551	RYVLDDEYTSSVGSK	+
Caspase 8	Q14790	Y380	TDSEEQPYLEMDLSS
Caspase 8	Q14790	Y448	TILTEVNYEVSNKDD
CD19	P15391	Y500	TSLGSQSYEDMRGIL
CD19	P15391	Y531	HEEDADSYENMDNPD
CDK2	P24941	Y15	EKIGEGTYGVVYKAR	-
CDK4	P11802	Y17	AEIGVGAYGTVYKAR	-
CK2a1 (CSNK2A1)	P68400	S194	EYNVRVASRYFKGPE	+
CK2a1 (CSNK2A1)	P68400	S2	______MSGPVPSRA
CK2a1 (CSNK2A1)	P68400	Y255	VLGTEDLYDYIDKYN
CSF2RB	P32927	Y466	ALRFCGIYGYRLRRK
CSF2RB	P32927	Y468	RFCGIYGYRLRRKWE
CSF2RB	P32927	Y822	VLQQVGDYCFLPGLG	?
CSF2RB	P32927	Y882	KALKQQDYLSLPPWE	?
DAPP1	Q9UN19	Y139	KVEEPSIYESVRVHT
DOK2	O60496	Y271	LPRPDSPYSRPHDSL
DOK2	O60496	Y299	PRGQEGEYAVPFDAV
DOK2	O60496	Y345	PPRPDHIYDEPEGVA
EpoR	P19235	Y489	DGPYSNPYENSLIPA	?
EpoR	P19235	Y504	AEPLPPSYVACS___	?
FcGR2A	P12318	Y304	TDDDKNIYLTLPPND
FcGR2B	P31994	Y292	GAENTITYSLLMHPD
FcGR2C	P31995	Y310	TDDDKNIYLTLPPND
GCET2	Q8N6F7	Y107	GNSAEEYYENVPCKA
GCET2	Q8N6F7	Y128	LGGTETEYSLLHMPS
GluR2	P42262	Y876	YKEGYNVYGIESVKI
GRP58	P30101	Y445	ANDVPSPYEVRGFPT
GRP58	P30101	Y454	VRGFPTIYFSPANKK
GRP58	P30101	Y467	KKLNPKKYEGGRELS
HS1 (HCLS1)	P14317	Y222	MEAPTTAYKKTTPIE	+
LAB	Q9GZY6	Y110	RHGSEEAYIDPIAME
LAB	Q9GZY6	Y118	IDPIAMEYYNWGRFS
LAB	Q9GZY6	Y119	DPIAMEYYNWGRFSK
LAB	Q9GZY6	Y136	EDDDANSYENVLICK
LAB	Q9GZY6	Y95	EDPASSRYQNFSKGS
LPXN	O60711	Y72	NIQELNVYSEAQEPK
Lyn	P07948	Y397	RVIEDNEYTAREGAK	+
NIPP-1	Q12972	Y335	NEPKKKKYAKEAWPG
NMT1	P30419	Y117	EEASKRSYQFWDTQP
NMT1	P30419	Y180	YTLLNENYVEDDDNM	+
p27Kip1	P46527	T187	NAGSVEQTPKKPGLR	+
p27Kip1	P46527	Y88	KGSLPEFYYRPPRPP	?
PAG (PAG1)	Q9NWQ8	Y381	GEEPEPDYEAIQTLN
PAG (PAG1)	Q9NWQ8	Y387	SEEPEPDYEAIQTLN
PAG (PAG1)	Q9NWQ8	Y417	LVPKENDYESISDLQ
PAG (PAG1)	Q9NWQ8	Y431	LTVPESTYTSIQGDP
PKCd (PRKCD)	Q05655	Y155	IKQAKIHYIKNHEFI	-
PKCd (PRKCD)	Q05655	Y313	SSEPVGIYQGFEKKT	+
PKCd (PRKCD)	Q05655	Y334	MQDNSGTYGKIWEGS	?
PKCd (PRKCD)	Q05655	Y52	VQKKPTMYPEWKSTF	-
PKCd (PRKCD)	Q05655	Y567	IRVDTPHYPRWITKE	-
PTEN	P60484	Y240	RREDKFMYFEFPQPL	+
PTPN6 (SHP1)	P29350	Y564	SKHKEDVYENLHTKN	+
RGS16	O15492	Y168	TLMEKDSYPRFLKSP
RGS16	O15492	Y177	RFLKSPAYRDLAAQA
SLAM/SLAMF1	Q13291	Y327	ETNSITVYASVTLPE
SLC4A1	P02730	Y21	ENLEQEEYEDPDIPE
SLC4A1	P02730	Y359	AKPDSSFYKGLDLNG
SLC4A1	P02730	Y8	MEELQDDYEDMMEEN
SLC4A1	P02730	Y904	EEEGRDEYDEVAMPV
SNCA	P37840	Y125	VDPDNEAYEMPSEEG
STAT5A	P42229	Y694	LAKAVDGYVKPQIKQ	+
Syk	P43405	Y323	STVSFNPYEPELAPW	+
Syk	P43405	Y348	LPMDTEVYESPYADP	+
Syk	P43405	Y352	TEVYESPYADPEEIR	+
TIF1B	Q13263	Y449	PMEVQEGYGFGSGDD	+
TIF1B	Q13263	Y458	FGSGDDPYSSAEPHV	+
TIF1B	Q13263	Y517	PGSTTEDYNLIVIER	+
TRIM28	Q13263	Y458	FGSGDDPYSSAEPHV	+
TRIM28	Q13263	Y517	PGSTTEDYNLIVIER	+
TRPV4	Q9HBA0	Y253	IERRCKHYVELLVAQ
WASP	P42768	Y291	AETSKLIYDFIEDQG	+

Protein Kinase Specificity

Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites

Matrix Type:

Experimentally derived from alignment of 106 known protein substrate phosphosites and 110 peptides phosphorylated by recombinant Lyn in vitro tested in-house by Kinexus.

Domain #:

Inhibitors

For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's

Based on in vitro and/or in vivo phosphorylation data

Compound Name	KD, Ki or IC50 (nM)	PubChem ID	ChEMBL ID	PubMed ID

Dasatinib	Ki = 130 pM	11153014	1421	15546730
CHEMBL1784637	IC50 < 150 pM	46864270	1784637	21561767
Ponatinib	IC50 = 240 pM	24826799		20513156
Staurosporine	IC50 = 490 pM	5279		19397322
PD173955	Kd = 2.2 nM	447077	386051	22037378
CHEMBL249097	IC50 = 3 nM	25138012	249097	17600705
CHEMBL364623	IC50 = 4 nM	11153014	364623	17154512
Bosutinib	Kd = 4.2 nM	5328940	288441	22037378
Foretinib	Kd = 9.1 nM	42642645	1230609	22037378
AST-487	Kd = 14 nM	11409972	574738	18183025
Bafetinib	IC50 = 19 nM	24853523		16105974
CHEMBL436137	IC50 = 21 nM	11719421	436137	16931012
Lck Inhibitor	IC50 < 25 nM	6603792		22037377
CHEMBL230686	Ki = 25.9 nM	11562302	230686	17113292
Kinome_714	IC50 = 26 nM	46886323		20346655
CHEMBL1092754	IC50 = 27.7 nM	44541014	1092754	20188552
SureCN5520662	IC50 = 28 nM	24766030	477817	18606543
DCC2036	IC50 = 29 nM	25066467
BML-275	IC50 > 50 nM	11524144	478629	22037377
GSK-3 Inhibitor IX	IC50 > 50 nM	5287844	409450	22037377
PP121	IC50 < 50 nM	24905142		18849971
SU11652	IC50 > 50 nM	24906267	13485	22037377
TWS119	IC50 > 50 nM	9549289	405759	22037377
Masitinib	Kd = 61 nM	10074640		22037378
AT9283	IC50 > 100 nM	24905142		19143567
BMS-690514	Kd < 100 nM	11349170		21531814
Nilotinib	Kd = 100 nM	644241	255863	22037378
Vandetanib	Kd = 110 nM	3081361	24828	18183025
Aloisine A	IC50 > 150 nM	5326843	75680	22037377
Alsterpaullone; 2-Cyanoethyl	IC50 > 150 nM	16760286	260138	22037377
Cdk1/2 Inhibitor III	IC50 > 150 nM	5330812	261720	22037377
GSK-3 Inhibitor X	IC50 > 150 nM	6538818	430226	22037377
Hesperadin	Kd < 150 nM	10142586	514409	19035792
IDR E804	IC50 > 150 nM	6419764	1802727	22037377
K-252a; Nocardiopsis sp.	IC50 > 150 nM	3813	281948	22037377
Ki11502	IC50 > 150 nM			22037377
N-Benzoylstaurosporine	IC50 > 150 nM	56603681	608533	22037377
Src Kinase Inhibitor I	IC50 > 150 nM	1474853	97771	22037377
SU6656	IC50 > 150 nM	5353978	605003	22037377
SureCN7018367	Kd < 150 nM	18792927	450519	19035792
Motesanib	Kd = 160 nM	11667893	572881	18183025
Lestaurtinib	Kd = 190 nM	126565		22037378
Nintedanib	IC50 = 195 nM	9809715	502835	18559524
Ibrutinib	IC50 = 200 nM	24821094	1873475	21958547
Imatinib	IC50 = 220 nM	123596	941	17376680
AG1478	IC50 > 250 nM	2051	7917	22037377
Alsterpaullone	IC50 > 250 nM	5005498	50894	22037377
Compound 56	IC50 > 250 nM	2857	29197	22037377
Flt-3 Inhibitor II	IC50 > 250 nM	11601743	377193	22037377
JAK3 Inhibitor VI	IC50 > 250 nM	16760524		22037377
SB218078	IC50 > 250 nM	447446	289422	22037377
SU11274	IC50 > 250 nM	9549297	261641	22037377
Syk Inhibitor	IC50 > 250 nM	6419747	104279	22037377
WHI-P154	IC50 > 250 nM	3795	473773	22037377
Cediranib	Kd = 270 nM	9933475	491473	22037378
Sunitinib	Kd = 270 nM	5329102	535	18183025
NVP-TAE684	Kd = 280 nM	16038120	509032	22037378
SureCN2934634	IC50 = 290 nM	45375865	1080994	19854645
BGJ398	IC50 = 300 nM	53235510		21936542
CHEMBL307152	IC50 < 300 nM	11655119	307152	12824014
TG101209	IC50 < 300 nM	16722832		17541402
Dovitinib	Kd = 370 nM	57336746		18183025
RAF265	Kd = 370 nM	11656518	558752	18183025
Alisertib	IC50 < 500 nM	24771867		22016509
BPIQ-I	IC50 = 500 nM	2427		22037377
Pazopanib	IC50 = 500 nM	10113978	477772	22037377
PP1 Analog II; 1NM-PP1	IC50 = 500 nM	5154691	573578	22037377
TG101348	Kd = 500 nM	16722836	1287853	22037378
Tozasertib	IC50 = 500 nM	5494449	572878	22037377
AMG458	IC50 = 506 nM	16086104	386661	18553959
Erlotinib	Kd = 530 nM	176870	553	18183025
Ki-20227	Kd = 710 nM	9869779	1908396	22037378
Pelitinib	Kd = 720 nM	6445562	607707	18183025
Canertinib	Kd = 780 nM	156414	31965	15711537
SU14813	Kd = 810 nM	10138259	1721885	18183025
Neratinib	Kd = 820 nM	9915743	180022	22037378
CUDC-101	IC50 = 840 nM	24756910	598797	20143778
Crizotinib	Kd = 940 nM	11626560	601719	22037378
Doramapimod	IC50 = 960 nM	156422	103667	22014550
Gefitinib	Kd = 990 nM	123631	939	18183025
CGP74514A	IC50 > 1 µM	2794188	367625	22037377
CHEMBL566515	Kd < 1 µM	44478401	566515	19788238
Flt-3 Inhibitor III	IC50 > 1 µM	11772958		22037377
Indirubin-3′-monoxime	IC50 > 1 µM	5326739		22037377
JNJ-10198409	IC50 > 1 µM	9797370	120077	22037377
Kenpaullone	IC50 > 1 µM	3820	296586	22037377
MK5108	IC50 > 1 µM	24748204		20053775
PD158780	IC50 > 1 µM	4707	53753	22037377
Purvalanol A	IC50 > 1 µM	456214	23327	22037377
Silmitasertib	IC50 > 1 µM	24748573		21174434
SNS314	IC50 > 1 µM	16047143	514582	18678489
SureCN10063060	Ki > 1 µM	52936621		21391610
WZ3146	Kd > 1 µM	44607360		20033049
WZ4002	Kd > 1 µM	44607530		20033049
PLX4720	Kd = 1.1 µM	24180719	1230020	22037378
SureCN5632345	Kd < 1.25 µM	44593646	515466	19035792
MLN8054	Kd = 1.4 µM	11712649	259084	18183025
Barasertib	Kd = 1.6 µM	16007391	215152	18183025
Kinome_2553	Ki > 1.6 µM	16007116	377383	16854050
CHEMBL248757	Ki > 1.667 µM	44444843	248757	17935989
CHEMBL1240703	Kd = 1.7 µM	52945601	1240703	19654408
JNK Inhibitor VIII	Ki > 1.7 µM	11624601	210618	16759099
Kinome_3027	Ki > 1.7 µM	11640926	378627	16759099
Kinome_3028	Ki > 1.7 µM	11590363	210928	16759099
VX745	Kd = 1.7 µM	3038525	119385	18183025
Momelotinib	IC50 > 2 µM	25062766		19295546
CHEMBL451523	IC50 = 2.4 µM	9917045	451523	19356929
Sorafenib	Kd = 3 µM	216239	1336	18183025
KW2449	Kd = 3.1 µM	11427553	1908397	22037378
SureCN4875304	IC50 > 3.5 µM	46871765		20472445
JNJ-28871063	IC50 > 4 µM	17747413		17975007
Ponatinib	IC50 = 160 pM	24826799		20513156
Staurosporine	IC50 = 490 pM	5279		19397322
Dasatinib	IC50 < 25 nM	11153014	1421	22037377
PP121	IC50 < 25 nM	24905142		18849971
Bosutinib	IC50 > 50 nM	5328940	288441	22037377
Dovitinib	IC50 > 50 nM	57336746		22037377
Lck Inhibitor	IC50 > 50 nM	6603792		22037377
SU6656	IC50 = 130 nM	5353978	605003	18077363
GSK-3 Inhibitor IX	IC50 > 150 nM	5287844	409450	22037377
Masitinib	IC50 > 150 nM	10074640		22037377
SU11652	IC50 > 150 nM	24906267	13485	22037377
TWS119	IC50 > 150 nM	9549289	405759	22037377
K-252a; Nocardiopsis sp.	IC50 > 250 nM	3813	281948	22037377
Ki11502	IC50 > 250 nM			22037377
PDK1/Akt/Flt Dual Pathway Inhibitor	IC50 > 250 nM	5113385	599894	22037377
Src Kinase Inhibitor I	IC50 > 250 nM	1474853	97771	22037377
Compound 56	IC50 = 500 nM	2857	29197	22037377
GSK-3 Inhibitor X	IC50 = 500 nM	6538818	430226	22037377
IDR E804	IC50 = 500 nM	6419764	1802727	22037377
JAK3 Inhibitor VI	IC50 = 500 nM	16760524		22037377
Nilotinib	IC50 = 500 nM	644241	255863	22037377
SU11274	IC50 = 500 nM	9549297	261641	22037377
Vemurafenib	IC50 = 599 nM	42611257	1229517	20823850
BML-275	IC50 > 1 µM	11524144	478629	22037377
Cdk1/2 Inhibitor III	IC50 > 1 µM	5330812	261720	22037377
Flt-3 Inhibitor II	IC50 > 1 µM	11601743	377193	22037377
Gefitinib	IC50 > 1 µM	123631	939	22037377
Pazopanib	IC50 > 1 µM	10113978	477772	22037377
WHI-P154	IC50 > 1 µM	3795	473773	22037377

Disease Linkage

General Disease Association:

Cancer, neurological disorders

Specific Diseases (Non-cancerous):

Chorea-Acanthocytosis; Acanthocytosis

Specific Cancer Types:

Sarcomas

Comments:

LYN appears to be an oncoprotein (OP). Lyn is constitutively phosphorylated and activated in cells of chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) patients. Abnormally enhanced expression levels of activation of Lyn signalling can be critical in survival and proliferation of some types of cancers.

Gene Expression in Cancers:

TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Barrett's esophagus epithelial metaplasia (%CFC= +309, p<0.0001); Bladder carcinomas (%CFC= +85, p<0.002); Brain glioblastomas (%CFC= -98, p<0.002); Brain oligodendrogliomas (%CFC= -54, p<0.088); Cervical cancer (%CFC= -71, p<0.0001); Clear cell renal cell carcinomas (cRCC) (%CFC= +90, p<0.0009); Colon mucosal cell adenomas (%CFC= +47, p<0.0001); Large B-cell lymphomas (%CFC= +90, p<0.019); Oral squamous cell carcinomas (OSCC) (%CFC= +604, p<0.0001); Papillary thyroid carcinomas (PTC) (%CFC= +81, p<0.096); Pituitary adenomas (ACTH-secreting) (%CFC= -53, p<0.053); Prostate cancer - metastatic (%CFC= +46, p<0.0001); and Skin squamous cell carcinomas (%CFC= +102, p<0.0009). The COSMIC website notes an up-regulated expression score for LYN in diverse human cancers of 404, which is 0.9-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 19 for this protein kinase in human cancers was 0.3-fold of the average score of 60 for the human protein kinases.

Mutagenesis Experiments:

Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.

Mutation Rate in All Cancers:

Percent mutation rates per 100 amino acids length in human cancers: 0.08 % in 25188 diverse cancer specimens. This rate is only 12 % higher than the average rate of 0.075 % calculated for human protein kinases in general.

Mutation Rate in Specific Cancers:

Highest percent mutation rates per 100 amino acids length in human cancers: 0.49 % in 805 skin cancers tested; 0.43 % in 1093 large intestine cancers tested; 0.32 % in 602 endometrium cancers tested.

Frequency of Mutated Sites:

None > 3 in 20,440 cancer specimens

Comments:

Only 3 deletions, and no insertions or complex mutations are noted on the COSMIC website.

COSMIC Entry:

LYN

OMIM Entry:

165120

Nomenclature

Short Name:

Full Name:

Alias:

Classification

Type:

Group:

Family:

SubFamily:

Specific Links

General Links

Structure

Mol. Mass (Da):

# Amino Acids:

# mRNA Isoforms:

mRNA Isoforms:

4D Structure:

1D Structure:

3D Image (rendered using PV Viewer):

PDB ID

Subfamily Alignment

Domain Distribution:

Kinexus Products

hiddentext

Post-translation Modifications

Myristoylated:

Palmitoylated:

Serine phosphorylated:

Threonine phosphorylated:

Tyrosine phosphorylated:

Ubiquitinated:

Distribution

Human Tissue Distribution

% Max Expression: Mean Expression: Number of Samples: Standard Deviation:

% Max Expression: Mean Expression: Number of Samples: Standard Deviation:

Evolution

Species Conservation

PhosphoNET % Identity: PhosphoNET % Similarity: Homologene %Identity:

PhosphoNET % Identity: PhosphoNET % Similarity: Homologene %Identity:

Regulation

Activation:

Inhibition:

Synthesis:

Degradation:

Kinections Map

Known Upstream Kinases

Based on in vitro and/or in vivo phosphorylation data

Known Downstream Substrates

Based on in vitro and/or in vivo phosphorylation data

Protein Kinase Specificity

Matrix Type:

Domain #:

Inhibitors

Based on in vitro and/or in vivo phosphorylation data

Disease Linkage

General Disease Association:

Specific Diseases (Non-cancerous):

Specific Cancer Types:

Comments:

Gene Expression in Cancers:

Mutagenesis Experiments:

Mutation Rate in All Cancers:

Mutation Rate in Specific Cancers:

Frequency of Mutated Sites:

Comments:

COSMIC Entry:

OMIM Entry:

% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:

% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:

PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:

PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity: